Clin Osteol 2018; 23(1): 38-41

Hypophosphatemic rickets linked to the X (XLH) chromosome -⁠ KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. PurkyněGuidelines

Palička Vladimír; Bayer Milan; Rosa Jan; Kutílek ©těpán

Received 5. 9. 2018

Received: September 5, 2018; Published: June 11, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palička V, Bayer M, Jan R, Kutílek ©. Hypophosphatemic rickets linked to the X (XLH) chromosome -⁠ KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyně. Clinical Osteology. 2018;23(1):38-41.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burnett CH, Dent CE, Harper C et al. Vitamin D-Resistant Rickets. Analysis of Twenty-Four Pedigrees with Hereditary and Sporadic Cases. Am J Med 1964; 36 : 222-232. Go to original source...
    2. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 2005; 16(9): 2565-2575. Go to original source...
    3. Beck-Nielsen SS, Brock-Jacobsen B, Gram Jet al. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 2009; 160(3): 491-497. Go to original source...
    4. Rafaelsen SH, Johansson S, Raeder H et al. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes and treatment complications. Eur J Endocrinol 2015; 174(2): 125-136. Go to original source...
    5. Endo I, Fukumoto S, Ozono K et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015; 62(9):811-816. Go to original source...
    6. Carpenter TO. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 1997; 44(2): 443-466. Go to original source...
    7. de Paula FJ, Rosen CJ. Bone Remodeling and Energy Metabolism: New Perspectives. Bone Res 2013; 1(1): 72-84. Go to original source...
    8. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137(2): 203-220. Go to original source...
    9. Glorieux FH, Marie PJ, Pettifor JM et al. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980; 303(18): 1023-1031. Go to original source...
    10. Imel EA, DiMeglio LA, Hui SLet al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010; 95(4): 1846-1850. Go to original source...
    11. Carpenter TO, Imel EA, Holm IA et al. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26(7): 1381-1388. Go to original source...
    12. Beck-Nielsen H. The metabolic syndrome in the daily clinic. Ugeskr Laeger 2010; 172(23): 1746-1751.
    13. Berndt M, Ehrich JH, Lazovic D et al. Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol 1996; 45(1): 33-41.
    14. Hardy DC, Murphy WA, Siegel BA et al. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 1989; 171(2): 403-414. Go to original source...
    15. Reid IR, Hardy DC, Murphy WA et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 1989; 68(6): 336-352. Go to original source...
    16. Whyte M et al. Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody for X-linked Hypophosphatemia (XLH): Final 64-Week Results of a Randomized, Open-label Phase 2. Study of 52 Children. Oral presentation 1154. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA.
    17. Carpenter TO et al. Effects of Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody, on Functional Outcomes in Children with X-linked Hypophosphatemia (XLH): Final Results from a Randomized, 64-week, Open-label Phase 2 Study Oral presentation 331. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA.
    18. Imel EA et al. Oral presentation at the ICCBH 2017; Würzburg, Germany.
    19. Imel EA et al. The Effects of Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody, on Phosphate Metabolism and Rickets in 1 to 4-Year-Old Children with X-linked Hypophosphatemia (XLH). Oral presentation 695. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA. Go to original source...
    20. Makitie O, Doria A, Kooh SW et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003; 88(8): 3591-3597. Go to original source...
    21. Quinlan C, Guegan K, Offiah A et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012; 27(4): 581-588. Go to original source...
    22. Informace dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02526160>.
    23. Informace dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02163577>.
    24. 24. Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomo
    25. gram. Ann Clin Biochem 2000; 37(Pt 1): 79-81. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.